CSOP Biotech (03174.HK) rises 1.21%, 4 ministries issue drug use rules
- CSOP Hang Seng Biotech ETF (03174.HK) rose 1.21% intraday to HK$3.676 on turnover of HK$1.22m.
- The ETF tracks the Hang Seng Biotech Index, has HK$930m in assets and a board lot of 100 shares.
NewTimeSpace News: As of 15:06 HKT on November 10, 2026, CSOP Hang Seng Biotech ETF (03174.HK) rose 1.21% intraday, with the latest price at HK$3.676, turnover of HK$1.22m, volume of 327,900 shares and a turnover rate of 0.13%.
The ETF is managed by CSOP Asset Management Limited and tracks the Hang Seng Biotech Index, covering biotech companies listed in Hong Kong. As of 15:06 HKT on November 10, 2026, its assets under management stood at HK$930m, with net asset value per unit of HK$3.622 and a board lot of 100 shares.
According to the National Health Commission's website, the NHC, the National Healthcare Security Administration, the National Administration of Traditional Chinese Medicine and the National Disease Control and Prevention Administration issued a notice requiring hospitals at the secondary level and above to streamline approval processes and include innovative drugs in their formularies in a timely manner.
CITIC Securities noted that domestic healthcare financing rose 48.63% year on year in the first ten months of 2026, with biopharma remaining the largest destination for capital.
- CSOP Hang Seng Biotech(03174.HK) up 1.17%, ESMO opens in Madrid today
- CSOP Biotech(03174.HK) down 2.50%, InnoCare-Lilly pact up to $3.25bn
- CSOP Hang Seng Biotech ETF (03174.HK) Up 4.32% as FDA Grants Priority Review to BeiGene Combo
- CSOP HS Biotech(03174.HK) +2.81%, Hengrui 9M net profit up 20.38%
- Chinese Innovative Drugs Set Record Share of ESMO Late-Breaking Abstracts; CSOP Hang Seng Biotech ETF (03174.HK) Rises 0.81% Intraday
